Cancer immunotherapy and targeted therapy advances

First CAR-T approval for solid tumor (gastric cancer) in China. Daraxonrasib nearly doubles pancreatic cancer survival (6.7→13.2 months) via molecular glue mechanism; FDA accelerated review expected 2026. CAR-T for glioblastoma via spinal fluid leads to complete tumor disappearance. TAA-T cell therapy for DIPG shows three children with no evidence of disease up to 5 years. Access barriers: only 20-25% of eligible lymphoma patients receive CAR-T. Off-the-shelf CAR-T developers target access gap; vispa-cel shows 82% ORR, 67% CR in 2L LBCL. Germline genetics influence CAR-T safety/efficacy. Teclistamab and cilta-cel show PFS/OS benefit in RRMM. SMARCA4-dNSCLC responds to ICI chemoimmunotherapy. Dual TIGIT/PD-1 blockade yields 17.2% ORR in ICI-refractory HCC. Phase III trial of live biotherapy MO-03 with immunotherapy underway. New: Enfortumab vedotin + pembrolizumab FDA approved for MIBC (47% lower risk of progression). New: Dato-DXd + pembrolizumab shows >50% response in treatment-naive NSCLC. New: amfAR commits $1.92M for HIV cure studies. New: Early CAR-T therapy in AML shows complete remissions. New: Sumitomo's enzomenib receives FDA orphan designation for ALL. New: Vaccine to prevent pancreatic cancer (mKRAS-VAX) shows 90% immune response, lesion resolution in early trial. New: Vista trial begins dosing ITOP1 precision cancer vaccine for esophageal adenocarcinoma. New: Adjuvant immunotherapy in early lung cancer continues to fail; field shifting to neoadjuvant (CheckMate 816, KEYNOTE-671). New: ICI+chemo outperforms bevacizumab+chemo in first-line non-squamous NSCLC (retrospective study). New: J&J options in vivo CAR-T maker Sail for $2.58B, signaling next-gen cell therapy. New: AI in cancer immunotherapy overview (LORIS, SCORPIO models). New: RP1 + nivolumab shows 33.6% ORR, 16.4% CR in anti-PD-1 refractory melanoma; FDA panel votes 10-3 for efficacy. New: In vivo CAR gene therapy review highlights promise and safety concerns. New: Immunogenomic classification of solid tumours refines patient selection for ICB therapy. New: First UK patient dosed with personalized lung cancer vaccine using Touchlight's dbDNA platform (Phase I). New: Kelun-Biotech's Sac-TMT gains NMPA review for first-line advanced TNBC, expanding ADC momentum. New: CAR NK therapy advance: immature cord blood NK subset drives trogocytosis; depleting it enhances function. New: NanoKar Therapeutics builds next-gen CAR-T platform for multiple cancers. New: CREATE acquires Monash's TP1107 LNP capture system to solve in vivo CAR-T liver tropism, 8-fold increase in target cell binding. New: clinTALL precision medicine tool for pediatric T-ALL using machine learning. New: Practical CAR T use in multiple myeloma preview highlights operational workflows, access barriers, and sequencing. New: CMC strategic priority: 74% of FDA CRLs from quality/manufacturing issues; early CMC planning and AI-driven process control critical for therapy access. New: CAR-T for T-ALL/T-LL: off-the-shelf, 91% ORR, 72.7% CR in heavily pretreated, enabling transplant access. New: Beyond PD-L1/TMB: TME, TLS, ctDNA emerging as biomarkers for immunotherapy response. New: Complement C3 local vs systemic role in immunotherapy; potential to identify patients and mimic effect. New: Clinical trial launched for KRAS G12D inhibitor VS-7375 at NYU for solid tumors. New: mRNA personalized vaccines for breast cancer emerging as potential paradigm shift. New: Therapeutic mRNA vaccines for HIV reviewed, highlighting self-amplifying RNA and LNP delivery innovations. New: FDA approved Pluvicto (177Lu-PSMA-617) for earlier use in PSMA-positive mHSPC, showing 28% reduction in progression/death risk, nearly doubling eligible patient population. New: PROTAC-controlled CAR T cells offer reversible safety switch, addressing on-target off-tumor toxicity. New: mRNA therapeutics beyond vaccines expanding into cancer and rare genetic diseases, reinforcing platform potential. New: CRISPR-edited donor stem cells (CD33 removal) combined with CD33-targeted maintenance therapy shows engraftment and stable counts in AML/MDS. New: Cevostamab bispecific antibody shows >40% response in Phase I multiple myeloma. New: Olomorasib (KRAS G12C inhibitor) gets second Breakthrough Therapy for pancreatic cancer. New: TUSC2 gene therapy in NSCLC shows TROP2 as predictive biomarker for nanoparticle uptake, enabling AI-guided patient selection. New: Checkpoint inhibitors not contraindicated in all interstitial lung disease, nuanced guidance. New: CLL CAR-T bridge therapy with pirtobrutinib shows real-world sequencing signal. New: IL-10–expressing CAR T-cell therapy in DLBCL shows 84.6% CR with ultra-low dosing in Phase I. New: Microbiome modulation with metronidazole boosts chemotherapy delivery via bile acid/Kupffer cell mechanism (preclinical). New: Inherited genetic variants (STXBP2, ADAMTSL3, PTPN22) influence CAR T toxicity and expansion, adding personalized medicine layer to cell therapy. New: R-Pola-Glo shows 90% response and 81% CR in frail older DLBCL with QoL improvements. New: Amplia Therapeutics partners with Lilly on FAK inhibitor narmafotinib to overcome KRAS G12C resistance in NSCLC. New: Endobronchial intratumoral delivery of immuno/gene therapies for NSCLC reviewed as potential local approach. Recent articles: Targeting FcRH5 in multiple myeloma (early CAR-T perspective) and TNBC immunotherapy guide (2026) reinforce momentum.